SCHEMBL2366072

SCHEMBL2366072

Cc1cc(C)c(N2CCN(C(=O)c3ccc(N4C(=O)OC[C@H]4C)cc3F)CC2)nc1C

nearest known ligand 0.40

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.40
KMT2A Q03164 1/20 0.40
IDH1 O75874 7/20 0.39
KDM4E B2RXH2 1/20 0.38
CPS1 P31327 3/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
TSHR P16473 1/20 0.36
GBA1 P04062 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366077 1.00 HTT (0.40) HTTKMT2AIDH1KDM4ECPS1
Hydrochloric Acid SCHEMBL2546014 0.99 HTT (0.39) HTTKMT2AIDH1KDM4ECPS1
Hydrochloric Acid SCHEMBL2546017 0.99 HTT (0.39) HTTKMT2AIDH1KDM4ECPS1
SCHEMBL2366672 0.93 GBA1 (0.37) HTTKMT2AIDH1KDM4ELMNA
SCHEMBL2366667 0.93 GBA1 (0.37) HTTKMT2AIDH1KDM4ELMNA
Hydrochloric Acid SCHEMBL2366073 0.87 SLC6A9 (0.34) IDH1GBA1
Hydrochloric Acid SCHEMBL2366080 0.87 SLC6A9 (0.34) IDH1GBA1
SCHEMBL15015187 0.87 ALDH1A1 (0.40) HTTKMT2AKDM4ELMNAMAPT
SCHEMBL2366827 0.86 IDH1 (0.42) HTTKMT2AIDH1KDM4EMAPT
SCHEMBL2366562 0.86 IDH1 (0.40) HTTKMT2AIDH1KDM4ECPS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed
WO-2010050461-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE 田辺三菱製薬株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 HTT 1580/4885KMT2A 800/4885IDH1 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.